Cargando…

Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter

Background: Changing the term/concept of the non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction associated fatty liver disease (MAFLD) may broaden the pathological definition that can include chronic renal involvement, and, possibly, changes chronic kidney disease's (CKD's)...

Descripción completa

Detalles Bibliográficos
Autores principales: Marc, Luciana, Mihaescu, Adelina, Lupusoru, Raluca, Grosu, Iulia, Gadalean, Florica, Bob, Flaviu, Chisavu, Lazar, Olariu, Nicu, Tucicovschi, Vlad, Timar, Bogdan, Sporea, Ioan, Timar, Romulus, Schiller, Adalbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793847/
https://www.ncbi.nlm.nih.gov/pubmed/35096879
http://dx.doi.org/10.3389/fmed.2021.788881
_version_ 1784640696252104704
author Marc, Luciana
Mihaescu, Adelina
Lupusoru, Raluca
Grosu, Iulia
Gadalean, Florica
Bob, Flaviu
Chisavu, Lazar
Olariu, Nicu
Tucicovschi, Vlad
Timar, Bogdan
Sporea, Ioan
Timar, Romulus
Schiller, Adalbert
author_facet Marc, Luciana
Mihaescu, Adelina
Lupusoru, Raluca
Grosu, Iulia
Gadalean, Florica
Bob, Flaviu
Chisavu, Lazar
Olariu, Nicu
Tucicovschi, Vlad
Timar, Bogdan
Sporea, Ioan
Timar, Romulus
Schiller, Adalbert
author_sort Marc, Luciana
collection PubMed
description Background: Changing the term/concept of the non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction associated fatty liver disease (MAFLD) may broaden the pathological definition that can include chronic renal involvement, and, possibly, changes chronic kidney disease's (CKD's) epidemiological association with liver disease, because CKD is associated with metabolic disorders and almost all patients with CKD present some form of an atherogenic dyslipidemia. Our study explores the relationship between MAFLD and CKD using Transient Elastography (TE) with a Controlled Attenuated Parameter (CAP). Methods: We evaluated 335 patients with diabetes with MAFLD and with high CKD risk using TE with CAP (FibroScan®). The CKD was defined according to Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines. Logistic regression and stepwise multiple logistic regression were used to evaluate the factors associated with CKD. In addition, a receiver operating characteristic curve (ROC) analysis was used to assess the performance of CAP and TE in predicting CKD and its optimal threshold. Results: The prevalence of CKD in our group was 60.8%. Patients with CKD had higher mean liver stiffness measurements (LSM) and CAP values than those without CKD. We found that hepatic steatosis was a better predictor of CKD than fibrosis. Univariate regression showed that CAP values >353 dB/m were predictive of CKD; while the multivariate regression analysis (after adjustment according to sex, body mass index (BMI), low-density lipoprotein cholesterol (LDLc), and high-density lipoprotein cholesterol (HDLc), and fasting glucose) showed that CAP values >353 dB/m were more strongly associated with the presence of CKD compared to the LSM (fibrosis) values. Conclusion: In patients with MAFLD, CAP-assessed steatosis appears to be a better predictor of CKD compared to LSM-assessed hepatic fibrosis.
format Online
Article
Text
id pubmed-8793847
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87938472022-01-28 Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter Marc, Luciana Mihaescu, Adelina Lupusoru, Raluca Grosu, Iulia Gadalean, Florica Bob, Flaviu Chisavu, Lazar Olariu, Nicu Tucicovschi, Vlad Timar, Bogdan Sporea, Ioan Timar, Romulus Schiller, Adalbert Front Med (Lausanne) Medicine Background: Changing the term/concept of the non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction associated fatty liver disease (MAFLD) may broaden the pathological definition that can include chronic renal involvement, and, possibly, changes chronic kidney disease's (CKD's) epidemiological association with liver disease, because CKD is associated with metabolic disorders and almost all patients with CKD present some form of an atherogenic dyslipidemia. Our study explores the relationship between MAFLD and CKD using Transient Elastography (TE) with a Controlled Attenuated Parameter (CAP). Methods: We evaluated 335 patients with diabetes with MAFLD and with high CKD risk using TE with CAP (FibroScan®). The CKD was defined according to Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines. Logistic regression and stepwise multiple logistic regression were used to evaluate the factors associated with CKD. In addition, a receiver operating characteristic curve (ROC) analysis was used to assess the performance of CAP and TE in predicting CKD and its optimal threshold. Results: The prevalence of CKD in our group was 60.8%. Patients with CKD had higher mean liver stiffness measurements (LSM) and CAP values than those without CKD. We found that hepatic steatosis was a better predictor of CKD than fibrosis. Univariate regression showed that CAP values >353 dB/m were predictive of CKD; while the multivariate regression analysis (after adjustment according to sex, body mass index (BMI), low-density lipoprotein cholesterol (LDLc), and high-density lipoprotein cholesterol (HDLc), and fasting glucose) showed that CAP values >353 dB/m were more strongly associated with the presence of CKD compared to the LSM (fibrosis) values. Conclusion: In patients with MAFLD, CAP-assessed steatosis appears to be a better predictor of CKD compared to LSM-assessed hepatic fibrosis. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8793847/ /pubmed/35096879 http://dx.doi.org/10.3389/fmed.2021.788881 Text en Copyright © 2022 Marc, Mihaescu, Lupusoru, Grosu, Gadalean, Bob, Chisavu, Olariu, Tucicovschi, Timar, Sporea, Timar and Schiller. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Marc, Luciana
Mihaescu, Adelina
Lupusoru, Raluca
Grosu, Iulia
Gadalean, Florica
Bob, Flaviu
Chisavu, Lazar
Olariu, Nicu
Tucicovschi, Vlad
Timar, Bogdan
Sporea, Ioan
Timar, Romulus
Schiller, Adalbert
Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title_full Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title_fullStr Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title_full_unstemmed Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title_short Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
title_sort liver steatosis: better predictor of ckd in mafld than liver fibrosis as determined by transient elastography with controlled attenuation parameter
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793847/
https://www.ncbi.nlm.nih.gov/pubmed/35096879
http://dx.doi.org/10.3389/fmed.2021.788881
work_keys_str_mv AT marcluciana liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT mihaescuadelina liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT lupusoruraluca liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT grosuiulia liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT gadaleanflorica liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT bobflaviu liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT chisavulazar liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT olariunicu liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT tucicovschivlad liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT timarbogdan liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT sporeaioan liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT timarromulus liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter
AT schilleradalbert liversteatosisbetterpredictorofckdinmafldthanliverfibrosisasdeterminedbytransientelastographywithcontrolledattenuationparameter